73 related articles for article (PubMed ID: 19509251)
21. Dinaciclib, a Bimodal Agent Effective against Endometrial Cancer.
Howard D; James D; Murphy K; Garcia-Parra J; Pan-Castillo B; Rex S; Moul A; Jones E; Bilbao-Asensio M; Michue-Seijas S; Lutchman-Singh K; Margarit L; Francis LW; Rees P; Gonzalez D; Conlan RS
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33800911
[TBL] [Abstract][Full Text] [Related]
22. Discovery and Characterization of a Chemical Probe for Cyclin-Dependent Kinase-Like 2.
Bashore FM; Min SM; Chen X; Howell S; Rinderle CH; Morel G; Silvaroli JA; Wells CI; Bunnell BA; Drewry DH; Pabla NS; Ultanir SK; Bullock AN; Axtman AD
bioRxiv; 2024 May; ():. PubMed ID: 38798634
[TBL] [Abstract][Full Text] [Related]
23. CDK Inhibitors and FDA: Approved and Orphan.
Cicenas J; Simkus J
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672637
[TBL] [Abstract][Full Text] [Related]
24. Antineoplastic Effects of Ankaferd Hemostat.
Malkan UY; Haznedaroglu IC
Biomed Res Int; 2022; 2022():2665903. PubMed ID: 35958818
[TBL] [Abstract][Full Text] [Related]
25. Cancer Metabolism and the Evasion of Apoptotic Cell Death.
Sharma A; Boise LH; Shanmugam M
Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31405035
[TBL] [Abstract][Full Text] [Related]
26. The therapeutic potential of cell cycle targeting in multiple myeloma.
Maes A; Menu E; Veirman K; Maes K; Vand Erkerken K; De Bruyne E
Oncotarget; 2017 Oct; 8(52):90501-90520. PubMed ID: 29163849
[TBL] [Abstract][Full Text] [Related]
27. Proteomic and transcriptomic analyses to explain the pleiotropic effects of Ankaferd blood stopper.
Simsek C; Selek S; Koca M; Haznedaroglu IC
SAGE Open Med; 2017; 5():2050312117722569. PubMed ID: 28839937
[TBL] [Abstract][Full Text] [Related]
28. Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax.
Bajpai R; Matulis SM; Wei C; Nooka AK; Von Hollen HE; Lonial S; Boise LH; Shanmugam M
Oncogene; 2016 Jul; 35(30):3955-64. PubMed ID: 26640142
[TBL] [Abstract][Full Text] [Related]
29. Targeting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin.
Dalva-Aydemir S; Bajpai R; Martinez M; Adekola KU; Kandela I; Wei C; Singhal S; Koblinski JE; Raje NS; Rosen ST; Shanmugam M
Clin Cancer Res; 2015 Mar; 21(5):1161-71. PubMed ID: 25542900
[TBL] [Abstract][Full Text] [Related]
30. Investigating and targeting chronic lymphocytic leukemia metabolism with the human immunodeficiency virus protease inhibitor ritonavir and metformin.
Adekola KU; Dalva Aydemir S; Ma S; Zhou Z; Rosen ST; Shanmugam M
Leuk Lymphoma; 2015 Feb; 56(2):450-9. PubMed ID: 24828872
[TBL] [Abstract][Full Text] [Related]
31. Identification of a novel Mcl-1 protein binding motif.
Placzek WJ; Sturlese M; Wu B; Cellitti JF; Wei J; Pellecchia M
J Biol Chem; 2011 Nov; 286(46):39829-35. PubMed ID: 21953453
[TBL] [Abstract][Full Text] [Related]
32. The cyclin-dependent kinase inhibitor SCH 727965 (dinacliclib) induces the apoptosis of osteosarcoma cells.
Fu W; Ma L; Chu B; Wang X; Bui MM; Gemmer J; Altiok S; Pledger WJ
Mol Cancer Ther; 2011 Jun; 10(6):1018-27. PubMed ID: 21490307
[TBL] [Abstract][Full Text] [Related]
33. Synthetic lethal interactions for the development of cancer therapeutics: biological and methodological advancements.
Mizuarai S; Kotani H
Hum Genet; 2010 Dec; 128(6):567-75. PubMed ID: 20976469
[TBL] [Abstract][Full Text] [Related]
34. Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM.
Wiedemeyer WR; Dunn IF; Quayle SN; Zhang J; Chheda MG; Dunn GP; Zhuang L; Rosenbluh J; Chen S; Xiao Y; Shapiro GI; Hahn WC; Chin L
Proc Natl Acad Sci U S A; 2010 Jun; 107(25):11501-6. PubMed ID: 20534551
[TBL] [Abstract][Full Text] [Related]
35. Expression levels of p18INK4C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines.
Eguchi T; Itadani H; Shimomura T; Kawanishi N; Hirai H; Kotani H
Mol Cancer Ther; 2009 Jun; 8(6):1460-72. PubMed ID: 19509251
[TBL] [Abstract][Full Text] [Related]
36. Potent anti-tumor activity of a macrocycle-quinoxalinone class pan-Cdk inhibitor in vitro and in vivo.
Hirai H; Takahashi-Suziki I; Shimomura T; Fukasawa K; Machida T; Takaki T; Kobayashi M; Eguchi T; Oki H; Arai T; Ichikawa K; Hasako S; Kodera T; Kawanishi N; Nakatsuru Y; Kotani H; Iwasawa Y
Invest New Drugs; 2011 Aug; 29(4):534-43. PubMed ID: 20084424
[TBL] [Abstract][Full Text] [Related]
37. An important role of CDK inhibitor p18(INK4c) in modulating antigen receptor-mediated T cell proliferation.
Kovalev GI; Franklin DS; Coffield VM; Xiong Y; Su L
J Immunol; 2001 Sep; 167(6):3285-92. PubMed ID: 11544316
[TBL] [Abstract][Full Text] [Related]
38. The expression of p18INK4 and p27kip1 cyclin-dependent kinase inhibitors is regulated differently during human B cell differentiation.
Schrantz N; Beney GE; Auffredou MT; Bourgeade MF; Leca G; Vazquez A
J Immunol; 2000 Oct; 165(8):4346-52. PubMed ID: 11035070
[TBL] [Abstract][Full Text] [Related]
39. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
Senderowicz AM
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S61-73. PubMed ID: 12819936
[TBL] [Abstract][Full Text] [Related]
40. [Molecular mechanisms controlling the cell cycle: fundamental aspects and implications for oncology].
Viallard JF; Lacombe F; Belloc F; Pellegrin JL; Reiffers J
Cancer Radiother; 2001 Apr; 5(2):109-29. PubMed ID: 11355576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
